David S. Snyder, MD, FACP, Srdan Verstovsek, MD, PhD, and Ruben Mesa, MD, FACP 

In this episode, “Clinical Developments in Myeloproliferative Neoplasms”, David Snyder, MD, Srdan Verstovsek, MD, PhD and Ruben Mesa, MD consider the evolution of JAK inhibitor therapy for myelofibrosis (MF).

The JAK inhibitor ruxolitinib is the cornerstone of medical therapy for MF and hydroxyurea-resistant/intolerant polycythemia vera (PV). However, there remain significant clinical needs and many management strategies continue to be studied. A notable advance is the 2019 approval of oral fedratinib, which is providing a second JAK inhibitor option for patients with MF. Promising results are also seen with various ruxolitinib combinations. For transplantation, new molecular prognostic scoring systems are increasingly being incorporated in decision-making. Current strategies for managing MPN symptoms include both pharmacologic and non-pharmacologic interventions.

Share this story, choose your platform!